📣 VC round data is live. Check it out!
- Public Comps
- Lunit
Lunit Valuation Multiples
Discover Lunit's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like HealthStream, Diagnósticos da América, Yidu Tech, Lumexa Imaging and more.
Lunit Overview
About Lunit
Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression.
Founded
2013
HQ

Employees
312
Website
Financials (LTM)
EV
$812M
Valuation Multiples
Start free trialLunit Financials
Lunit reported last 12-month revenue of $60M and negative EBITDA of ($34M).
In the same LTM period, Lunit generated $60M in gross profit, ($34M) in EBITDA losses, and had net loss of ($38M).
Revenue (LTM)
Lunit P&L
In the most recent fiscal year, Lunit reported revenue of $55M and EBITDA of ($7M).
Lunit is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (13%), and net margin of (57%).
Financial data powered by Morningstar, Inc.
Lunit Stock Performance
Lunit has current market cap of $741M, and enterprise value of $812M.
Market Cap Evolution
Lunit's stock price is $9.97.
Lunit share price decreased by 10.5% in the last 30 days, and by 74.2% in the last year.
Lunit has an EPS (earnings per share) of $-0.42.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $812M | $741M | -6.2% | -10.5% | -55.0% | -74.2% | $-0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLunit Valuation Multiples
Lunit trades at 13.5x EV/Revenue multiple, and (23.7x) EV/EBITDA.
EV / Revenue (LTM)
Lunit Financial Valuation Multiples
As of June 3, 2026, Lunit has market cap of $741M and EV of $812M.
Lunit has a P/E ratio of (19.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lunit Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lunit Margins & Growth Rates
Lunit grew revenue by 23% and EBITDA by 235% in the last fiscal year.
In the most recent fiscal year, Lunit reported gross margin of 100%, EBITDA margin of (13%), and net margin of (57%).
Lunit Margins
Lunit Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Lunit Operational KPIs
Lunit's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Lunit's Rule of 40 is (13%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lunit's Rule of X is 21% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Lunit Competitors
Lunit competitors include HealthStream, Diagnósticos da América, Yidu Tech, Lumexa Imaging, Craneware, RaySearch Labs, Lumibird, Equasens, Echo IQ and Jiangsu Bioperfectus.
Most Lunit public comparables operate across Medical Imaging & Diagnostics, Healthcare Software, HealthTech, B2B SaaS, Vertical SaaS and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.2x | 2.2x | 9.5x | 9.3x | |||
| 0.9x | 1.0x | 5.0x | 5.0x | |||
| 4.0x | - | (31.6x) | - | |||
| 1.6x | 1.6x | 7.1x | 7.0x | |||
| 3.4x | 3.1x | 10.7x | 10.0x | |||
| 5.2x | 5.2x | 12.0x | 11.7x | |||
| 2.9x | 2.9x | 15.0x | 13.9x | |||
| 2.3x | 2.3x | 7.8x | 8.1x | |||
This data is available for Pro users. Sign up to see all Lunit competitors and their valuation data. Start Free Trial | ||||||
Lunit VC Funding History
Before going public, Lunit raised $137M in total equity funding, across 7 rounds.
Last private valuation of Lunit was $153M, after raising $26M in December 2019 from IMM Investment, InterVest Co., Kakao Ventures, and 4 other investors.
Lunit Funding Rounds
Acquisitions by Lunit
Lunit has acquired 1 company to date.
Last acquisition by Lunit was on December 14th 2023. Lunit acquired Volpara Health for $193M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Lunit
| Description | Volpara Health is a Seattle-headquartered developer of AI-driven software for breast cancer screening and risk assessment. The platform analyzes mammograms to quantify breast density, identify masking risk, and recommend personalized screening pathways for radiologists worldwide. Listed on the ASX, Volpara integrates with systems from GE Healthcare, Hologic, and Siemens Healthineers across North America, Europe, and Asia-Pacific. |
| HQ Country | |
| HQ City | Wellington |
| Deal Date | 14 Dec 2023 |
| Valuation | $193M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Lunit acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lunit
| When was Lunit founded? | Lunit was founded in 2013. |
| Where is Lunit headquartered? | Lunit is headquartered in South Korea. |
| How many employees does Lunit have? | As of today, Lunit has over 312 employees. |
| Is Lunit publicly listed? | Yes, Lunit is a public company listed on Korea Exchange. |
| What is the stock symbol of Lunit? | Lunit trades under 328130 ticker. |
| When did Lunit go public? | Lunit went public in 2022. |
| Who are competitors of Lunit? | Lunit main competitors include HealthStream, Diagnósticos da América, Yidu Tech, Lumexa Imaging, Craneware, RaySearch Labs, Lumibird, Equasens, Echo IQ, Jiangsu Bioperfectus. |
| What is the current market cap of Lunit? | Lunit's current market cap is $741M. |
| What is the current revenue of Lunit? | Lunit's last 12 months revenue is $60M. |
| What is the current revenue growth of Lunit? | Lunit revenue growth (NTM/LTM) is 22%. |
| What is the current EV/Revenue multiple of Lunit? | Current revenue multiple of Lunit is 13.5x. |
| Is Lunit profitable? | No, Lunit is not profitable. |
| What is the current EBITDA of Lunit? | Lunit has negative EBITDA and is not profitable. |
| What is Lunit's EBITDA margin? | Lunit's last 12 months EBITDA margin is (57%). |
| What is the current EV/EBITDA multiple of Lunit? | Current EBITDA multiple of Lunit is (23.7x). |
| What is the current FCF of Lunit? | Lunit's last 12 months FCF is ($36M). |
| What is Lunit's FCF margin? | Lunit's last 12 months FCF margin is (60%). |
| What is the current EV/FCF multiple of Lunit? | Current FCF multiple of Lunit is (22.7x). |
| How many companies Lunit has acquired to date? | As of June 2026, Lunit has acquired 1 company. |
| What was the largest acquisition by Lunit? | $193M acquisition of Volpara Health on 14th December 2023 was the largest M&A Lunit has done to date. |
| What companies Lunit acquired? | Lunit acquired Volpara Health. |
| In how many companies Lunit has invested to date? | Lunit hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Lunit
Lists including Lunit
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
